Fluorescent Probes Reveal How Tirzepatide Targets Pancreas and Brain Cells
Key Insights
Scientists developed fluorescent probes called daLUXendins (search) to track how dual agonist drugs like tirzepatide interact with cells in the pancreas and brain.
The imaging technique revealed that tirzepatide binds to multiple pancreatic cell types including beta, alpha, and delta cells, and reaches brain regions involved in appetite regulation.
Researchers discovered that drug receptors form tiny clusters called nanodomains in the pancreas, which may explain how dual agonists amplify metabolic signals.
An international research team has developed a groundbreaking imaging approach to visualize how dual agonist drugs like tirzepatide interact with cells in the pancreas and brain. Published in Nature Metabolism, the study provides the first detailed view of how these breakthrough diabetes (search) and obesity (search) treatments achieve their superior therapeutic effects.
The researchers created fluorescently tagged versions of dual-acting molecules that mimic tirzepatide's effects, called daLUXendins (search). These chemical tools allow scientists to track how drugs that activate both glucagon-like peptide-1 receptor (search) (GLP-1R (search)) and glucose-dependent insulinotropic polypeptide receptor (search) (GIPR (search)) move through the body and bind to specific cell types.
Mapping Drug Targets Across Multiple Cell Types
Until now, the exact cellular targets of dual agonist drugs remained unclear due to limitations in antibody-based detection methods. The new fluorescent probes revealed that tirzepatide binds strongly to multiple pancreatic cell types, with signal intensity showing β cells > α cells = δ cells. This broader cellular targeting offers insight into the range of metabolic effects triggered by dual agonists.
"By using our new dual fluorescent probes, we can now track the receptors simultaneously in live tissues and identify which cells respond to treatment," said study co-author Professor David Hodson from the Radcliffe Department of Medicine at the University of Oxford. "This provides a powerful tool for understanding how dual agonists achieve their metabolic effects."
Brain Targeting and Appetite Regulation
The imaging technique also revealed how tirzepatide reaches brain regions involved in appetite control. The researchers visualized the drug targeting specialist cells known as tanycytes that monitor nutrient signals and communicate with feeding centers. Systemic administration of daLUXendin strongly labeled GLP1R+ and GIPR (search)+ neurons in circumventricular organs characterized by an incomplete blood-brain barrier.
"We are particularly interested in the dynamics of the peptides," said study lead Dr Johannes Broichhagen from Leibniz-FMP (search). The brain targeting helps explain how dual agonists regulate appetite, though the study found that brain penetration beyond circumventricular organs was limited and similar to single agonists.
Receptor Clustering Reveals Amplification Mechanism
Using super-resolution microscopy, the team discovered that receptors form tiny clusters or 'nanodomains' in the pancreas. At the single-molecule level, daLUXendin targets endogenous GLP1R-GIPR (search) nanodomains, which differ in organization and composition from those targeted by single agonists. This clustering may help explain how dual agonists amplify metabolic signals through cumulative effects.
The findings exclude a role for enhanced brain penetration in determining the superior efficacy of dual agonists compared to single GLP-1R (search) agonists, shedding new light on different modes of action between these therapeutic approaches.
Implications for Next-Generation Therapies
The research provides important insights into why dual agonists like tirzepatide show superior efficacy for glucose lowering and weight reduction compared to single GLP-1R (search) agonists. The daLUXendins (search) demonstrated potent dual agonist activity with advantageous functional selectivity profiles, showing less bias toward mouse GLP1R over mouse GIPR (search).
While the research relied on mouse models and fluorescent surrogates of tirzepatide, the authors believe the approach can be adapted to human studies and expanded to include other targets, including new triple agonists that also act on glucagon receptors (search).
"The next step will be to see how these results differ from triple agonists, which are more effective again," said Hodson. The study raises new questions about what would happen if drugs' access to the brain were improved and how triple agonists with additional glucagon content achieve their enhanced therapeutic effects.
The imaging tools could accelerate the development of more effective treatments for diabetes (search) and obesity (search) by providing researchers with unprecedented visibility into how these complex multi-target drugs interact with cellular systems.